Placenta growth factor and sFlt-1 as biomarkers in ischemic heart disease and heart failure: a review

Area of Science:

• Cardiovascular Medicine
• Biomarker Discovery
• Molecular Regulation

Background:

• Coronary heart disease (CHD) and heart failure (HF) are major causes of morbidity and mortality.
• Identifying novel biomarkers is crucial for improving the management of CHD and HF.
• Placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) are key regulators in vascular biology.

Purpose of the Study:

• To summarize the molecular regulation of PlGF and sFlt-1.
• To evaluate the biomarker potential of PlGF and sFlt-1 in CHD and HF.
• To assess the predictive value of PlGF, sFlt-1, and their ratio in cardiovascular outcomes.

Main Methods:

• Review of existing literature on PlGF and sFlt-1 in CHD and HF.
• Analysis of studies investigating PlGF and sFlt-1 levels in relation to disease states.
• Examination of the combined use of PlGF/sFlt-1 with standard biomarkers for outcome prediction.

Main Results:

• PlGF levels are elevated during ischemia in CHD.
• Both PlGF and sFlt-1 are elevated in HF, with sFlt-1 showing stronger predictive power for outcomes.
• Combined use of PlGF, sFlt-1, or their ratio with standard biomarkers may enhance outcome predictions.

Conclusions:

• PlGF and sFlt-1 demonstrate promising biomarker potential for CHD and HF.
• Further rigorous studies are required to validate their clinical usefulness in detection and management.
• Understanding the molecular regulation is key to leveraging these proteins as diagnostic and prognostic tools.